Pharmaxis Ltd's (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) Gary Phillips speaks to Proactive's Andrew Scott following the news the US FDA has approved its cystic fibrosis treatment Bronchitol®. The milestone clears Bronchitol for sale in the US as an add‐on maintenance therapy to improve pulmonary function in cystic fibrosis (CF) patients 18 years of age and older.
viewPharmaxis Ltd
Pharmaxis CEO says US FDA approval for Bronchitol® is 'big day in company's history'
Quick facts: Pharmaxis Ltd
Price: 0.098 AUD
ASX:PXS
Market: ASX
Market Cap: $38.92 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Pharmaxis transformational Bronchitol FDA approval extends cash runway...
Most read
Tiziana Life Sciences hires scientist with track record of successfully...
2 days, 9 hours ago
Coronavirus: Synairgen starts final phase of treatment trials days after UK...
2 days, 2 hours ago
Open Orphan doses first volunteer with next-generation coronavirus vaccine
4 days, 9 hours ago
Tonix Pharmaceuticals forms second research collaboration with Massachusetts...
3 days, 21 hours ago
